CAR-T cells for autoimmune diseases
Part of Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy that targets two immune proteins (CD19 and BAFF) to treat autoimmune diseases like lupus or scleroderma. It is for people who have not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a diagnosed autoimmune disease (such as lupus, kidney inflammation, scleroderma, dermatomyositis, or neuromyelitis optica).
- Your disease must still be active after trying at least two standard treatments (like steroids, immune suppressants, or biologics) for over 6 months, or you must have no good treatment options after remission.
- You need to have enough white blood cells, red blood cells, and platelets (laboratory tests will confirm).
- You cannot have serious heart, kidney, or liver problems, active infections (like HIV, hepatitis B or C), or a history of seizures or stroke.
- If you are of childbearing age, you must use effective birth control for at least 6 months after the final treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of cell therapy (CAR-T cells) to see if it can help treat autoimmune diseases like lupus or scleroderma. If you qualify, you might get a chance to try this new approach that could help your immune system stop attacking your own body.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This trial tests a new treatment using your own immune cells, modified to target and calm the overactive immune system that causes autoimmune diseases. It may help reduce symptoms for conditions like lupus, scleroderma, and others.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.